Condition: Epilepsy · Sponsor: VA Office of Research and Development
Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy. In this study, participants will be assigned randomly (i.e., by flip of a coin), to a group that takes MPH and a group that takes a placebo (sugar pill). Participants will not know the group to which they have been assigned. Tests of attention and memory will be completed before taking the study pills and at Week 8. All participants will then have the option of taking MPH for the next two months, and attention and memory will be tested again at Week 16. The study will determine whether methylphenidate is helpful for the treatment of attention and memory problems in adults with epilepsy, and whether the medication is safe and beneficial when taken over an extended time period.
This description comes directly from the study's public registry record.
Beth A Leeman-Markowski, MD · (212) 686-7500 · beth.leeman-markowski@va.gov
Samantha P Martin, MA · (212) 685-7500 · Samantha.Martin1@va.gov
Always discuss trial participation with your own doctor first.
| Miami VA Healthcare System, Miami, FL | Miami, Florida, United States | Recruiting |
| VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA | Boston, Massachusetts, United States | Recruiting |
| VA NY Harbor Healthcare System, New York, NY | New York, New York, United States | Recruiting |
| VA Portland Health Care System, Portland, OR | Portland, Oregon, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04419272